• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生存还是毁灭:经济评价中的未来生命。

To be or not to be: Future lives in economic evaluation.

机构信息

Leuven Institute for Healthcare Policy, KU Leuven, Leuven, Belgium.

Department of Economics, KU Leuven, Leuven, Belgium.

出版信息

Health Econ. 2022 Jan;31(1):258-265. doi: 10.1002/hec.4454. Epub 2021 Nov 7.

DOI:10.1002/hec.4454
PMID:34743370
Abstract

Sometimes healthcare will affect the health of people living in the future, or their chance of coming into existence. Should such outcomes be valued in health-economic evaluation? Guidelines implicitly recommend their inclusion but this rule has counterintuitive implications and is not consistently applied in practice. We suggest making a distinction between "necessary" and "potential" future lives in Health Technology Assessment. Necessary lives will exist independent of our healthcare choices and should be included. Potential lives are choice-dependent and should be excluded. This rule offers intuitive solutions within the HTA framework, and it changes the cost-effectiveness of several interventions where necessary future lives are affected.

摘要

有时,医疗保健会影响未来生活在这个世界上的人的健康,或者影响他们的存在机会。在健康经济评估中,这些结果是否应该被重视?指南隐含地建议将其包括在内,但这条规则有违直觉,在实践中也没有得到一致应用。我们建议在卫生技术评估中对“必要”和“潜在”未来生命进行区分。必要的生命将独立于我们的医疗保健选择而存在,应该被包括在内。潜在的生命是取决于选择的,应该被排除在外。这条规则在 HTA 框架内提供了直观的解决方案,并且改变了一些必要未来生命受到影响的干预措施的成本效益。

相似文献

1
To be or not to be: Future lives in economic evaluation.生存还是毁灭:经济评价中的未来生命。
Health Econ. 2022 Jan;31(1):258-265. doi: 10.1002/hec.4454. Epub 2021 Nov 7.
2
Future Offspring Costs in Economic Evaluation.未来后代成本在经济评估中的应用。
Pharmacoeconomics. 2022 Feb;40(2):141-147. doi: 10.1007/s40273-021-01102-w. Epub 2021 Oct 29.
3
Over-, under- and misuse of pain treatment in Germany.德国疼痛治疗的过度、不足及不当使用情况。
GMS Health Technol Assess. 2011 Apr 19;7:Doc03. doi: 10.3205/hta000094.
4
Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.以心血管疾病和代谢综合征为例,说明作为一级预防一部分的项目的有效性。
GMS Health Technol Assess. 2011 Apr 1;7:Doc02. doi: 10.3205/hta000093.
5
Individual health services.个人健康服务。
GMS Health Technol Assess. 2011;7:Doc05. doi: 10.3205/hta000096. Epub 2011 Sep 15.
6
Methods for the health technology assessment of complex interventions: a protocol for a scoping review.复杂干预措施的卫生技术评估方法:一项范围综述方案
BMJ Open. 2020 Nov 30;10(11):e039263. doi: 10.1136/bmjopen-2020-039263.
7
Health technology assessment in Catalonia: an overview of past and future perspectives.加泰罗尼亚的卫生技术评估:过去与未来展望概述
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:88-93. doi: 10.1017/S0266462309090473. Epub 2009 Jun 12.
8
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework.超越医疗保健领域评估和奖励医疗干预措施的价值:概念框架。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):211-224. doi: 10.1007/s40273-024-01392-w. Epub 2024 May 17.
9
Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products.将环境溢出纳入医疗产品应用经济评估中。
Value Health. 2023 Aug;26(8):1270-1281. doi: 10.1016/j.jval.2023.03.008. Epub 2023 Mar 24.
10
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.先进治疗药物产品和健康技术评估——基于价值和可持续医疗保健的原则和实践。
Eur J Health Econ. 2019 Apr;20(3):427-438. doi: 10.1007/s10198-018-1007-x. Epub 2018 Sep 18.

引用本文的文献

1
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.系统评价将母婴、胎儿和儿童健康结局以及家庭溢出效应纳入成本效用分析的方法和实践。
Pharmacoeconomics. 2024 Aug;42(8):843-863. doi: 10.1007/s40273-024-01397-5. Epub 2024 May 31.
2
On spillovers in economic evaluations: definition, mapping review and research agenda.关于经济评估中的溢出效应:定义、映射综述和研究议程。
Eur J Health Econ. 2024 Sep;25(7):1239-1260. doi: 10.1007/s10198-023-01658-8. Epub 2024 Jan 23.
3
Valuing infertility treatment: Why QALYs are inadequate, and an alternative approach to cost-effectiveness thresholds.
重视不孕治疗:为何质量调整生命年(QALYs)并不充分,以及成本效益阈值的替代方法。
Front Med Technol. 2022 Dec 23;4:1053719. doi: 10.3389/fmedt.2022.1053719. eCollection 2022.
4
Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods.比较基因组和外显子组测序与传统诊断途径的成本效益框架:范围综述和推荐方法。
Genet Med. 2022 Oct;24(10):2014-2027. doi: 10.1016/j.gim.2022.06.004. Epub 2022 Jul 14.